What's Happening?
A nationwide survey in Australia reveals significant changes in testing protocols for respiratory illnesses following the COVID-19 pandemic. Laboratory identification of respiratory pathogens has gained increased importance for both epidemiological and clinical
reasons, particularly for respiratory syncytial virus (RSV), where new preventatives are nearing clinical translation. The study, which surveyed 45 out of 193 eligible NATA-accredited laboratories, found that 40% of responding laboratories reported over 80% of their molecular tests in 2023 were respiratory multiplex panels. Influenza viruses, RSV, and SARS-CoV-2 were the most frequently tested pathogens. While influenza typing (A or B) was included in nearly two-thirds of panels, RSV typing (A or B) was present in less than a quarter. There was considerable variability in testing platforms, with 37 laboratories using 87 different platforms. GeneXpert® (Cepheid) was the most common platform, especially in eastern states. Forty percent of laboratories reported changes to their respiratory testing procedures or panels in 2023 compared to the previous year, with results primarily reported directly to referring doctors and jurisdictional Departments of Health.
Why It's Important?
While this study focuses on Australia, its findings offer insights into global trends in infectious disease surveillance and laboratory practices, which are highly relevant to the U.S. healthcare system. The increased reliance on multiplex PCR panels for respiratory viruses signifies a shift towards more comprehensive and efficient diagnostic approaches. This is crucial for understanding disease burden, guiding clinical decisions, and evaluating the effectiveness of preventatives, especially for viruses like RSV that significantly impact vulnerable populations. The variability in testing platforms and reporting practices highlights potential challenges in standardizing surveillance data, which could affect national public health responses and resource allocation. For the U.S., similar trends in post-pandemic testing evolution would necessitate ongoing evaluation of laboratory capacity, standardization efforts, and integration of data for effective public health monitoring and outbreak management. The emphasis on laboratory diagnosis as a critical element in understanding disease burden directly impacts public health policy and vaccine development strategies.
What's Next?
The ongoing evolution of respiratory virus testing practices suggests a continued adaptation to post-pandemic public health needs. Laboratories in Australia, and likely in the U.S., will continue to refine their testing panels and procedures to optimize for efficiency, accuracy, and comprehensiveness. There may be a push for greater standardization of testing platforms and reporting mechanisms to improve data comparability and enhance national surveillance capabilities. The increasing importance of RSV diagnostics, driven by new preventatives, indicates a potential for more widespread RSV typing to better understand strain prevalence and vaccine efficacy. Further research and development in diagnostic technologies, particularly in multiplex panels, are anticipated to address emerging pathogens and improve turnaround times. Public health agencies will likely continue to work with laboratories to ensure that testing practices align with epidemiological needs and support timely public health interventions, including outbreak response and vaccination campaigns.
Beyond the Headlines
The shift towards multiplex respiratory virus testing reflects a broader transformation in infectious disease diagnostics, moving from single-pathogen detection to comprehensive syndromic approaches. This has profound implications for clinical practice, potentially leading to more precise diagnoses, reduced unnecessary antibiotic use, and improved patient outcomes. However, it also raises questions about the interpretation of complex multiplex results and the potential for over-diagnosis or incidental findings. From a public health perspective, the increased data generated by these panels offers a richer understanding of viral co-infections and seasonal patterns, which can inform more targeted public health messaging and interventions. The variability in testing practices across laboratories underscores the need for robust quality assurance programs and inter-laboratory collaboration to ensure consistency and reliability of surveillance data. Ultimately, this evolution in diagnostics is shaping a more sophisticated, but also more complex, landscape for managing respiratory infectious diseases.
